{"name":"Paradigm Biopharmaceuticals Ltd.","slug":"paradigm-biopharmaceuticals-ltd","ticker":"","exchange":"","domain":"paradigmbiopharmaceuticals.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Pentosan Polysulfate Sodium twice weekly","genericName":"Pentosan Polysulfate Sodium twice weekly","slug":"pentosan-polysulfate-sodium-twice-weekly","indication":"Interstitial cystitis/bladder pain syndrome","status":"phase_3"}]}],"pipeline":[{"name":"Pentosan Polysulfate Sodium twice weekly","genericName":"Pentosan Polysulfate Sodium twice weekly","slug":"pentosan-polysulfate-sodium-twice-weekly","phase":"phase_3","mechanism":"Pentosan polysulfate sodium is a semi-synthetic polysaccharide that reduces inflammation and may restore the glycosaminoglycan layer of the bladder epithelium.","indications":["Interstitial cystitis/bladder pain syndrome"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxOLVlJc3JXdTZCR3pKMHhLclJMV0NhYksyQzJjZm5vOENGSUFQRzFIdHBvdzFvYXB3a3pSWGQ3RWtHZEpHMEJJcHZJXy1HdnNsejQ3TzV0bmZoenBMeFBCbjZwWERaekl3ZVJ4amcxNDlkZzJlM2V4VXgwLVdKSnhXYzFMSUVtcUkzNHlTei1IM254eF9TeHBQZzJR?oc=5","date":"2026-04-06","type":"trial","source":"openPR.com","summary":"Knee Osteoarthritis Clinical Trial Pipeline Appears Robust - openPR.com","headline":"Knee Osteoarthritis Clinical Trial Pipeline Appears Robust","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-24","type":"pipeline","source":"simplywall.st","summary":"Can Paradigm Biopharmaceuticals' (ASX:PAR) Leadership Vision Drive Long-Term Strategic Value? - simplywall.st","headline":"Can Paradigm Biopharmaceuticals' (ASX:PAR) Leadership Vision Drive Long-Term Strategic Value?","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-23","type":"pipeline","source":"simplywall.st","summary":"Paradigm Biopharmaceuticals (ASX:PAR): Assessing Valuation as Investor Focus Builds Ahead of Ignite Summit Presentation - simplywall.st","headline":"Paradigm Biopharmaceuticals (ASX:PAR): Assessing Valuation as Investor Focus Builds Ahead of Ignite Summit Presentation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxOZTZJemt5T3Y1eW5uV0M4QVFIWWRtY1FsYjg0RTFuWHhkT2syT2tJUEEyMWJhLWVydGtYMDdWeVNOTS05R0lscWJqYi1BMzhGNGpxelVpTWxWVTdfSmRBNlg4dlF2YTFCVFZmNmdoaVBLMExvem5yRXVWTkVzUUJRS2VlRjV6VUpHRmN3ak12T216RjRm?oc=5","date":"2025-10-01","type":"earnings","source":"Yahoo Finance","summary":"Paradigm Biopharmaceuticals Limited's (ASX:PAR) Profit Outlook - Yahoo Finance","headline":"Paradigm Biopharmaceuticals Limited's (ASX:PAR) Profit Outlook","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPUUV0eS13elVUQ2g3YjhJem1JTUNSN0RLc0pKaEpab0xnUXlrRm00aHNkSENmNmZlamlCWGg0Q1ZBS0xSRFBJM2QyVC1IOFhUcG1PTDVJRWVFdlQ5bmZVYlVNY3VwWUpDUkRVaXpaNzBvSzNsX251RkxSNms1eTVFdG8tRjg4bUNNM3p4Z3p0dVFyN05vcTN6UkhFVi1scHM1d2p3Z0I1Qk9IUQ?oc=5","date":"2025-08-13","type":"pipeline","source":"intelligentinvestor.com.au","summary":"Paradigm Biopharmaceuticals: Full Steam Ahead - intelligentinvestor.com.au","headline":"Paradigm Biopharmaceuticals: Full Steam Ahead","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxORlEzRWgxN1lDYnp3end2RWJQRFIyNkZhQ3V5S1U2X2ZwOHR4RUlER0xMcmNpMUtqRkNScVNULUVnREt5T3FNZGViNDdTcHhYYkpqcmozMTFqemVKaUxJZEdweUMyNlNHSzUwX1NRTkgyc004b096ZEo4b1VhQy05ZmF6aDB0c0dDaEd1MzFLcGc?oc=5","date":"2025-07-24","type":"pipeline","source":"Market Index","summary":"PAR:ASX Announcement - Paradigm Investor Webinar - 24 Jul 2025 - Market Index","headline":"PAR:ASX Announcement - Paradigm Investor Webinar - 24 Jul 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxNUVF6eGpZUVQwYXdXZnpTUVN0aDc4eERxeXNqbC03NXZTWFZvZE5LLTZYNm43aDBleGhOZTRLOEtBczR0MWtHTlc5SjR3em53Tlc5Wmx5aWdGNU9WNUMxc3pDeWxGR2hOeGZxTHNTTUpCQncyZnNwcUpBSUtpcUdMRXF6cmVURG5OZndJOUx5WGNfSlU?oc=5","date":"2025-06-26","type":"pipeline","source":"The Motley Fool Australia","summary":"2 ASX healthcare stocks making huge moves on big news - The Motley Fool Australia","headline":"2 ASX healthcare stocks making huge moves on big news","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxNcGNkNGdscjhsMkpUeW9GbWQzTW1GcktTd003SFYzVlRmMC1EMThUc1dtdk8xcVNLV1Z2UGhTWkRQdm1SdGh1NENNaHg1azB3cGltc0ozWjlCSWROc2RMU2g0MG5hNEdRalFmdVNick9ELVliczRodklzelJYdXVxZ0NQcWFiVmRuTktvX0JDRQ?oc=5","date":"2025-03-29","type":"pipeline","source":"Yahoo Finance","summary":"Is Paradigm Biopharmaceuticals (ASX:PAR) In A Good Position To Invest In Growth? - Yahoo Finance","headline":"Is Paradigm Biopharmaceuticals (ASX:PAR) In A Good Position To Invest In Growth?","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-02-03","type":"pipeline","source":"The Australian","summary":"Paradigm eyes $110m raise with loyalty offer - The Australian","headline":"Paradigm eyes $110m raise with loyalty offer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPS2NzTlVHMkVJT2lvc0U0UDJMTVZxbzZjQkNnX0JxRDlHYXducE1GT0h3UWdVWDhhSmlxU2JfTXFkS2pFUk9YeXA4U3JGX0V2RmxTSF9pRWk2WVRBd1Q3eWdrekZxNHJSeXlGUkt1VEtmRkQtb3JFODd1bVMzc3QzQ21SVEtqUHh1VjhEc3JjZW9KZkJMbHBkVElFYV8?oc=5","date":"2022-06-27","type":"pipeline","source":"citybiz","summary":"Paradigm Biopharmaceuticals Appoints Marco Polizzi as CEO - citybiz","headline":"Paradigm Biopharmaceuticals Appoints Marco Polizzi as CEO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8wFBVV95cUxOSGFwQXhadGY2WGtLbHA3OGE5a3lxc1RHVWoyYmhETVEwc2hSZGN4aVpBRTBRdWs0MXZzRGpKczYzU09rZ1AwMzA3WkJHM3Z1WFJSbDlCbllEQklzOEI5QnByVEFtcnlySVdvaEIwOXhWSHFRUkwwVG1iUE9KbkxLcG4tT3NwWkJlUzU4dmxEdk40OE1HZVI2UkhQU21wWGVubElJYV84NHBZaEZrX1RBeTZMelJfRnFRRUhrZUNfYzRvdEFycUo1SFhfdHFGYUVGSl85RW5JODBqOHl3OGwwaG1URlJGQ3k1YjhwN21VcU5BeE0?oc=5","date":"2022-05-29","type":"pipeline","source":"Proactive financial news","summary":"Paradigm Biopharmaceuticals targets growth with appointment of US-based Marco Polizzi as CEO - Proactive financial news","headline":"Paradigm Biopharmaceuticals targets growth with appointment of US-based Marco Polizzi as CEO","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2019-01-18","type":"deal","source":"Newswise","summary":"Mount Sinai Partners with Paradigm Biopharmaceuticals Ltd. and ReqMed Company, Ltd. to Repurpose Drug to Battle Rare MPS Diseases | Newswise - Newswise","headline":"Mount Sinai Partners with Paradigm Biopharmaceuticals Ltd. and ReqMed Company, Ltd. to Repurpose Drug to Battle Rare MPS","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}